Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Array BioPharma, Inc.

Clinical Vignette SeriesTM in Melanoma: Leveraging Clinical Data on IO and BRAF/MEK to Inform Treatment Decision Making Across Lines of Care.

Release Date: July 31, 2020
Expiration Date: July 31, 2021

Activity Overview

The management of melanoma has shifted in recent years, with improved understanding of signaling pathways and resistance mechanisms underlying the pathogenesis of metastatic melanoma. This has led to advances in the development of targeted therapies. These new approaches have given physicians the ability to target previously unreachable treatment goals to improve patient outcomes. Novel treatments for advanced melanoma raise challenging questions, and uncertainty often arises regarding the best strategies for integrating new treatments into current treatment paradigms. The ability to evaluate the efficacy of new therapies, manage adverse events, and implement biomarkers for selecting therapy is critical for making informed decisions and optimizing patient care.

This educational activity uses a multimedia format combining written passages and brief audio interviews. Expert faculty review the impact of clinical data on patient care, discuss clinical cases, and share forward-looking perspectives on the treatment of advanced melanoma.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Array BioPharma, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists involved in the treatment and management of patients with melanoma. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals (HCPs) interested in the treatment of melanoma may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • discuss recent data concerning BRAF/MEK inhibition strategies, immunotherapies, and sequencing therapies for the management of melanoma in the adjuvant and metastatic setting;
  • implement strategies to recognize and manage treatment-related adverse events with immunotherapeutic and targeted treatments for melanoma; and
  • describe the importance and applicability of mutational and biomarker data to optimize the clinical management of patients with melanoma.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty:

Omid Hamid, MD
Omid Hamid, MD
Chief, Translational Research and Immuno-Oncology
Director, Cutaneous Malignancies
The Angeles Clinic and Research Institute
Director, Experimental Therapeutics
Cedars Sinai Medical Care Foundation
Los Angeles, CA

Disclosures: Grant Research Support: Arcus Biosciences Inc, Aduro Biotech Inc, Akeso Biopharma Inc, Amgen Inc, Array BioPharma Inc, Bristol Myers Squibb Co, CytomX Therapeutics Inc, Exelixis Inc, F. Hoffman-La Roche Ltd, Genentech Inc, GlaxoSmithKline plc, Immunocore Ltd, Incyte Corp, Iovance Biotherapeutics Inc, Merck & Co Inc, Moderna Inc, Merck Serono SA, NextCure Inc, Novartis AG, Sanofi SA/Regeneron Pharmaceuticals Inc, Seattle Genetics Inc, Torque Pharmaceuticals PVT Ltd, Zelluna Immunotherapy AS; Consultant: Aduro Biotech Inc, Akeso Biopharma Inc, Amgen Inc, Array BioPharma Inc, BeiGene Ltd, Bristol Myers Squibb Co, F. Hoffman-La Roche Ltd, Genentech Inc, GlaxoSmithKline plc, Immunocore Ltd, Incyte Corp, Janssen Pharmaceuticals Inc, Merck & Co Inc, NextCure Inc, Novartis AG, Sanofi SA/Regeneron Pharmaceuticals Inc, Seattle Genetics Inc, Tempus, Zelluna Immunotherapy AS; Speakers Bureau: Array BioPharma Inc, Bristol Myers Squibb Co, Novartis AG, Sanofi SA/Regeneron Pharmaceuticals Inc.

Ryan J. Sullivan, MD
Ryan J. Sullivan, MD
Assistant Professor of Medicine
Harvard Medical School
Director, Translational Research, Center for Melanoma
Medical Oncologist
Massachusetts General Hospital
Principal Investigator
Dana-Farber/Harvard Cancer Center
Boston, MA

Disclosures: Grant Research Support: Amgen Inc, Merck & Co Inc; Consultant: Amgen Inc, Compugen Ltd, Genentech Inc, Merck & Co Inc, Novartis AG, Replimune Group Inc, Syndax Pharmaceuticals Inc

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
3031
Filter By